Oric Pharmaceuticals, INC

ORIC Pharmaceuticals reported Q2 2026 results, highlighting the initiation of a global Phase 3 trial for rinzimetostat in prostate cancer and a cash runway extending into late 2028.

ORIC Pharmaceuticals, Inc. has amended its 2022 Inducement Equity Incentive Plan to increase the number of shares available for issuance.

ORIC Pharmaceuticals announced first quarter 2026 financial results, highlighting progress in its rinzimetostat and enozertinib clinical programs and a strong cash position extending runway into late 2028.

ORIC Pharmaceuticals, Inc. announced the launch of a new $200 million at-the-market equity offering program, following the sale of $139.7 million under its previous program.

ORIC Pharmaceuticals announced positive Phase 1b data for rinzimetostat and enozertinib, alongside a significantly extended cash runway into the second half of 2028.

ORIC Pharmaceuticals presented positive Phase 1b data for enozertinib (ORIC-114) in EGFR-mutated NSCLC, demonstrating strong systemic and CNS activity.

Oric Pharmaceuticals disclosed its second-quarter 2026 financial results, highlighting progress in its rinzimetostat and enozertinib clinical programs while reporting a net loss of $41.5 million.

Oric Pharmaceuticals reported increased R&D expenses and a net loss for Q1 2026, while advancing its rinzimetostat and enozertinib clinical programs and raising capital through ATM offerings.

ORIC Pharmaceuticals maintains a robust financial position into H2 2028, driven by recent capital raises and reports promising Phase 1b data for ORIC-944 in mCRPC.

ORIC Pharmaceuticals reports increased cash reserves and a strategic pipeline prioritization to advance its lead cancer drug candidates, ORIC-944 and ORIC-114, despite growing net losses.

ORIC Pharmaceuticals reports a net loss of $30.0 million for Q1 2025 and provides updates on its clinical programs, including ORIC-944 and ORIC-114.

ORIC Pharmaceuticals' third quarter 2024 report highlights increased R&D spending, a net loss, and sufficient cash to fund operations into late 2026.

ORIC Pharmaceuticals reports significant clinical progress for rinzimetostat and enozertinib, alongside successful capital raises, as it focuses on overcoming cancer resistance.

ORIC Pharmaceuticals details its 2024 financial results and provides updates on its clinical development programs, including ORIC-114 and ORIC-944.

ORIC Pharmaceuticals' 2023 annual report details clinical advancements and financial standing, emphasizing its focus on overcoming cancer resistance.

Richard A. Heyman, a Director of Oric Pharmaceuticals, Inc., sold 13,100 shares of common stock on July 24, 2026 for $12.02 per share.

Director Richard Heyman reported a sale of 41,800 shares of Oric Pharmaceuticals common stock on July 6, 2026, pursuant to a Rule 10b5-1 trading plan.

Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised stock options and subsequently sold 52,000 shares of common stock for a significant gain.

Oric Pharmaceuticals Director Richard A. Heyman sold 6,700 shares of common stock for approximately $80,430 through a pre-arranged 10b5-1 trading plan.

Oric Pharmaceuticals director Angie You received a grant of 40,000 stock options with a strike price of $8.17, vesting monthly over one year.

Oric Pharmaceuticals, Inc. Director Lori Anne Kunkel was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over one year.

ORIC Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to be held virtually, with key proposals including director elections, auditor ratification, and equity plan approval.

ORIC Pharmaceuticals will hold its annual stockholders meeting on June 11, 2025, with proposals including the election of directors and ratification of KPMG LLP as the independent auditor.

ORIC Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.

ORIC Pharmaceuticals will hold its annual meeting of stockholders on June 12, 2024, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

ORIC Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the appointment of its independent accounting firm.

SR One Capital Management and its affiliated funds have reported a decrease in their beneficial ownership of ORIC Pharmaceuticals, Inc. common stock to below 5%.

SR One Capital Management and its affiliated funds have acquired a significant 5.4% beneficial ownership stake in ORIC Pharmaceuticals, Inc. through a recent private placement of common stock and pre-funded warrants.

Viking Global Investors LP and associated entities reported a 7.8% beneficial ownership stake in Oric Pharmaceuticals, Inc. as of March 31, 2026.

Venrock Healthcare Capital Partners and affiliates report a 4.2% beneficial ownership stake in ORIC Pharmaceuticals, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Oric Pharmaceuticals, Inc.

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 5.4% in Oric Pharmaceuticals Inc., holding over 5.3 million shares.

Pfizer Inc. has reported a beneficial ownership of 3,442,940 shares, representing 3.3% of the outstanding common stock of ORIC Pharmaceuticals, Inc. as of March 31, 2026.

BlackRock, Inc. has reported a beneficial ownership of 5.6% of ORIC Pharmaceuticals Inc.'s common stock as of December 31, 2025.